Vera reported $114.7 million in cash, cash equivalents, and marketable securities as of December 31, 2022. Subsequent to December 31, 2022, the company raised approximately $107.6 million in net proceeds, after deducting underwriting discounts and commissions and offering expenses, from a public offering of its Class A common stock that was completed in February 2023.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VERA:
- Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Vera Therapeutics director buys $637K in common stock
- 3 Stocks Insiders Love
- Vera Therapeutics director Seidenberg buys $2.2M in common stock
- Vera Therapeutics director Enright buys $12.0M in common stock
